日本生物製藥市場報告（按適應症（自體免疫疾病、腫瘤、代謝紊亂及其他）、類別（重組蛋白、單株抗體、純化蛋白）和地區分類，2026-2034 年）

Japan Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 120 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本生物製藥市場規模達246億美元。展望未來， IMARC Group預計到2034年，該市場規模將達到365億美元，2026年至2034年期間的複合年成長率（CAGR）為4.51%。市場成長主要受以下幾個關鍵因素驅動：對客製化藥物的需求不斷成長、慢性病和生活方式相關疾病的發病率上升，以及生物技術的快速發展，尤其是在基因工程和重組DNA技術等領域。

本報告解答的關鍵問題

1.日本生物製藥市場的規模有多大？
2.日本生物製藥市場的成長預測如何？
3.哪些因素正在推動日本生物製藥市場的成長？

Japan biopharmaceutical market size reached USD 24.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 36.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.51% during 2026-2034. The market is experiencing growth due to several key factors, including an increasing need for customized medicines, the rising incidence of chronic and lifestyle-related illnesses, and rapid advancements in biotechnology, particularly in areas like genetic engineering and recombinant DNA technology.

Biopharmaceuticals, also referred to as biologics, belong to a category of pharmaceutical medications that originate from biological sources. These drugs are manufactured through biotechnological processes utilizing living organisms such as bacteria, yeast, or mammalian cells. In contrast to conventional small-molecule drugs synthesized chemically, biopharmaceuticals are characterized by their large and intricate molecular structures, which allow them to engage in highly precise interactions with biological targets within the body. Biopharmaceuticals offer numerous advantages over traditional pharmaceuticals. They often demonstrate a remarkable degree of specificity in their action, frequently targeting particular receptors or molecules. This specificity typically leads to enhanced effectiveness and a reduction in adverse side effects. Moreover, biopharmaceuticals hold the potential to treat diseases that were historically challenging to address using conventional drug approaches.

Japan Biopharmaceutical Market Trends:

In Japan, several factors are contributing to substantial market growth. Firstly, there is a notable surge in demand for personalized medicine, which is a significant driver. Additionally, the increased adoption of biopharmaceuticals for treating conditions such as cancer, diabetes, psoriasis, and rheumatoid arthritis is another key factor fueling this growth. Furthermore, there is a growing awareness among the general population regarding the effectiveness and accessibility of biopharmaceuticals, further propelling the regional market. Moreover, there is a heightened focus on addressing rare diseases and developing orphan drugs, which is driving market growth. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Besides this, governments and regulatory agencies have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions, which is acting as another significant growth-inducing factor. Furthermore, biopharmaceutical companies are actively investing in research and development (R&D) efforts to create orphan drugs targeting rare diseases. This approach not only addresses critical medical needs but also creates opportunities for expanding the market over the forecasted period.

Japan Biopharmaceutical Market Segmentation:

Indication Insights:

Autoimmune Diseases
Oncology
Metabolic Disorders
Others

Class Insights:

Recombinant Proteins
Monoclonal Antibodies
Purified Proteins

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report

1.What is the size of Japan's biopharmaceutical market?
2.What is the growth forecast of the Japan biopharmaceutical market?
3.What factors are driving the growth of the Japan biopharmaceutical market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biopharmaceutical Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biopharmaceutical Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Biopharmaceutical Market - Breakup by Indication

6.1 Autoimmune Diseases
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Oncology
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Metabolic Disorders
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Others
- 6.4.1 Historical and Current Market Trends (2020-2025)
- 6.4.2 Market Forecast (2026-2034)

7 Japan Biopharmaceutical Market - Breakup by Class

7.1 Recombinant Proteins
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Monoclonal Antibodies
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Purified Proteins
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)

8 Japan Biopharmaceutical Market - Breakup by Region

8.1 Kanto Region
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Breakup by Indication
- 8.1.4 Market Breakup by Class
- 8.1.5 Key Players
- 8.1.6 Market Forecast (2026-2034)
8.2 Kansai/Kinki Region
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Breakup by Indication
- 8.2.4 Market Breakup by Class
- 8.2.5 Key Players
- 8.2.6 Market Forecast (2026-2034)
8.3 Central/ Chubu Region
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Breakup by Indication
- 8.3.4 Market Breakup by Class
- 8.3.5 Key Players
- 8.3.6 Market Forecast (2026-2034)
8.4 Kyushu-Okinawa Region
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Breakup by Indication
- 8.4.4 Market Breakup by Class
- 8.4.5 Key Players
- 8.4.6 Market Forecast (2026-2034)
8.5 Tohoku Region
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2020-2025)
- 8.5.3 Market Breakup by Indication
- 8.5.4 Market Breakup by Class
- 8.5.5 Key Players
- 8.5.6 Market Forecast (2026-2034)
8.6 Chugoku Region
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2020-2025)
- 8.6.3 Market Breakup by Indication
- 8.6.4 Market Breakup by Class
- 8.6.5 Key Players
- 8.6.6 Market Forecast (2026-2034)
8.7 Hokkaido Region
- 8.7.1 Overview
- 8.7.2 Historical and Current Market Trends (2020-2025)
- 8.7.3 Market Breakup by Indication
- 8.7.4 Market Breakup by Class
- 8.7.5 Key Players
- 8.7.6 Market Forecast (2026-2034)
8.8 Shikoku Region
- 8.8.1 Overview
- 8.8.2 Historical and Current Market Trends (2020-2025)
- 8.8.3 Market Breakup by Indication
- 8.8.4 Market Breakup by Class
- 8.8.5 Key Players
- 8.8.6 Market Forecast (2026-2034)

9 Japan Biopharmaceutical Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Services Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Services Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Services Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Services Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Services Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Biopharmaceutical Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis